Hyperprolactinemia in postmenopausal women

被引:8
作者
Maor, Y
Berezin, M
机构
[1] TEL AVIV UNIV,CHAIM SHEBA MED CTR,INST ENDOCRINOL & METAB,IL-52621 TEL HASHOMER,ISRAEL
[2] TEL AVIV UNIV,CHAIM SHEBA MED CTR,DEPT INTERNAL MED A,IL-52621 TEL HASHOMER,ISRAEL
关键词
pituitary; prolactin; postmenopause; microadenoma; macroadenoma; luteinizing hormone; follicular stimulating hormone;
D O I
10.1016/S0015-0282(97)81368-4
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To study the clinical cause and course of hyperprolactinemia in postmenopausal women. Design: Retrospective case-note study. Setting: Tertiary care hospital. Patient(s): Six postmenopausal women with hyperprolactinemia. Main Outcome Measure(s): Clinical history and physical examination, serum levels of PRL, LH, FSH, computed tomography (CT) of the pituitary gland before and after treatment with bromocriptine. Result(s): At presentation, the mean age was 57.5 +/- 7.5 SD years. The mean level of PRL was 1,427 +/- 1,599 ng/mL (1,427 +/- 1,599 mu g/L). All women suffered from secondary amenorrhea for a mean duration of 31.8 +/- 5.6 years. Five of six had galactorrhea at some time in the past. Pituitary imaging revealed a pituitary macroadenoma in four women, an enlarged sella suggestive of a pituitary macroadenoma in one woman, and a microadenoma in one. After treatment with bromocriptine, the PRL level decreased in all women to within normal limits. Five of six women developed hot flushes after the PRL level returned to normal. Conclusion(s): Most cases of hyperprolactinemia in postmenopausal women are due to macroadenoma rather than microadenoma, the common finding in younger women. The clinical course is suggestive of a prolonged disease that was not detected earlier, although clinical signs were present. These findings are suggestive of an enlargement of microadenomas to macroadenomas as time passes. (C) 1997 by American Society for Reproductive Medicine.
引用
收藏
页码:693 / 696
页数:4
相关论文
共 17 条
[1]   PROLACTINOMA IN 53 MEN - CLINICAL CHARACTERISTICS AND MODES OF TREATMENT (MALE PROLACTINOMA) [J].
BEREZIN, M ;
SHIMON, I ;
HADANI, M .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 1995, 18 (06) :436-441
[2]  
BEREZIN M, 1993, ISR J OBSTET GYNECOL, V4, P173
[3]   DOPAMINE AGONISTS AND PITUITARY-TUMOR SHRINKAGE [J].
BEVAN, JS ;
WEBSTER, J ;
BURKE, CW ;
SCANLON, MF .
ENDOCRINE REVIEWS, 1992, 13 (02) :220-240
[4]  
Blankstein J., 1986, OVULATION INDUCTION
[5]   PHARMACOLOGIC CONTROL OF TEMPERATURE REGULATION [J].
COX, B ;
LOMAX, P .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1977, 17 :341-353
[6]  
Friesen H G, 1977, Clin Endocrinol (Oxf), V6 Suppl, p91S
[7]  
GOMEZ F, 1977, AM J MED, V62, P648, DOI 10.1016/0002-9343(77)90866-X
[8]   HYPERPROLACTINEMIA, AMENORRHEA, AND GALACTORRHEA [J].
KOPPELMAN, MCS ;
JAFFE, MJ ;
RIETH, KG ;
CARUSO, RC ;
LORIAUX, DL .
ANNALS OF INTERNAL MEDICINE, 1984, 100 (01) :115-121
[9]  
MACLEOD RM, 1976, GROWTH HORMONE RELAT, P443
[10]   LONGITUDINAL EVALUATION OF PATIENTS WITH UNTREATED PROLACTIN-SECRETING PITUITARY-ADENOMAS [J].
MARCH, CM ;
KLETZKY, OA ;
DAVAJAN, V ;
TEAL, J ;
WEISS, M ;
APUZZO, MLJ ;
MARRS, RP ;
MISHELL, DR .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1981, 139 (07) :835-844